Double‐needle yamane technique using flanged haptics in ocular trauma—a retrospective survey of visual outcomes and safety

To evaluate visual outcomes and safety of the double‐needle technique using flanged haptics (Yamane technique) in patients with aphakia caused by ocular trauma at a trauma referral center. Retrospective: Consecutive interventional case series of 30 patients who underwent the Yamane technique due to posttraumatic aphakia. The double‐needle technique using flanged haptics was combined with anterior vitrectomy (group A) in 14 patients, and with pars plana vitrectomy (PPV) (group B) due to retinal detachment, nucleus dislocation into the vitreous cavity, or intraocular lens (IOL) displacement in 16 patients. No intraoperative complications were noted. There was significant improvement in the visual acuity in both groups at the second postoperative visit. However, the visual acuity was significantly worse in the group treated with the Yamane technique combined with PPV. Silicone oil tamponade in PPV group was associated with worse visual acuity, whereas post lensectomy status was associated with poor visual function result in the anterior vitrectomy group. There was one case of slight IOL decentration and one retinal detachment during the postoperative follow‐up period in the group with PPV. In this case series, the Yamane technique applied in traumatized eyes was found to be an efficacious and safe procedure. Combining the Yamane technique with PPV due to posterior segment ocular trauma was associated with worse functional results in the follow‐up at three months. Further studies with longer follow‐up evaluations are required to verify long‐term complications

Processing and properties of Ag-clad BSCCO superconductors

Long lengths of mono- and multifilament Ag-clad BSCCO (Bi-Sr-Ca-Cu-O) conductors with critical current densities of >10{sup 4} A/cm{sup 2} at 77 K were fabricated by the powder-in-tube method. {Tc} magnets were assembled by stacking pancake coils fabricated from long tapes and then tested vs applied magnetic field at various temperatures. A magnet that contained {approx}2400 m of {Tc} conductor generated a field of 3.2 T at 4.2 K. In-situ tensile and bending properties of the Ag-clad conductors were studied. Multilayer Ag/superconductor composites were fabricated by chemical etching. Preliminary results with multilayer tapes show that continuous Ag reinforcement of the BSCCO core improves strain tolerance of the tapes so they can carry 90% of their initial I{sub c} at 1% bend strain desite a higher superconductor/Ag ratio than that of unreinforced tapes

Synchronous motion of two vertically excited planar elastic pendula

The dynamics of two planar elastic pendula mounted on the horizontally excited platform have been studied. We give evidence that the pendula can exhibit synchronous oscillatory and rotation motion and show that stable in-phase and anti-phase synchronous states always co-exist. The complete bifurcational scenario leading from synchronous to asynchronous motion is shown. We argue that our results are robust as they exist in the wide range of the system parameters.Comment: Submitte

Ozone-based eye drops activity on ocular epithelial cells and potential pathogens infecting the front of the eye

Confirmation of the biological effectiveness of new ophthalmic preparations introduced in the market is an important element in maintaining the safety of using this type of medications. This study aimed to investigate the activity of Ozodrop® on human corneal and conjunctival epithelial cells, as well as its antibacterial and antifungal activity. Cytotoxicity analyses of ocular surface epithelial cells were performed in vitro by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) and Neutral Red uptake assays. The level of nitric oxide released by the cells was assessed by the Griess method. The reduction of the DPPH (2,2-diphenyl-1-picrylhydrazyl) free radical by the tested formulation was analyzed. Microbiological tests were also performed. It was found that the Ozodrop® preparation exhibited biological activity, but was less active than the reference antibiotics and the anti-yeast agent. The cytotoxic activity of the Ozodrop® formulation was dependent on the time of cell exposure to it. No toxic effect was observed in the short-term, for up to 3 h. It appeared after 24 h of exposure of the cells to the preparation. The drops showed antioxidant activity in the specified concentration range. They also stimulated the release of nitric oxide, mainly by corneal epithelial cells. The Ozodrop® formulation exhibits biological activity that can be considered useful in the treatment of infections in the front part of the eye

Fabrication and characterization of (Bi,Pb)-Sr-Ca-Cu-O (2223) bars

Bulk bars for current lead applications were fabricated from (Bi,Pb)- Sr-Ca-Cu-O (Bi-2223) for low thermal conductivity and high critical current. Bars measuring 17.8 cm in length were made by uniaxially pressing Bi-2223 powder of controlled (1.7/0.34)223 and (1.8/0.4)223 phase composition. The bulk bars were densified by subjecting them to a schedule of alternate liquid-phase sintering and cold isostatic pressing. Liquid phase sintering temperatures were optimized from differential thermal analysis and microstructure morphology. Phase purity and microstructure were evaluated by x-ray diffraction and scanning electron microscopy. Low-resistance silver contacts were applied to the bars by hot-pressing at 820{degrees}C and 3 MPa. Critical current densities {approx} 1000 A/cm{sup 3} (critical currents of 750 A at 77 K in self-field conditions) were achieved

Processing and characterization of Ag-clad Bi-2223 superconductors

Practical applications of high-temperature superconductors will be governed by their current transport and mechanical characteristics. With careful control of the processing parameters high-quality long- length mono- and multifilament Bi-2223 conductors have been fabricated by the powder-in-tube technique. A critical current density (Jc) of up to 1.2 x 104 A cm{sup -2} has been observed at 77 K in a 1260-m-long multifilament conductor containing 37 monocore filaments. A high-temperature superconducting magnet and a prototype transformer were fabricated and characterized from such long-length conductors. Efforts further improve the current characteristics of the Bi-2223 tapes resulted in the development of the wire-in-tube technique. A Jc value >105 A cm{sup -2} at 77 K and in self field have been obtained in a Bi-2223 tape fabricated by the wire- in-tube method. Extensive studies on the in-situ strain characteristics of the mono- and multifilament conductors have been conducted. Multilayer silver/superconductor composite tapes, fabricated by a novel chemical etching technique, were also observed to exhibit improved strain tolerance characteristics

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Objective: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological anti-tumour necrosis factor (TNF) agents. Methods: In this phase 3, multicentre, placebo-controlled trial, 312 adults with active PsA were randomised (stratified by site, weight (≤100 kg/>100 kg), methotrexate use) to ustekinumab 45 mg or 90 mg at week 0, week 4, q12 weeks or placebo at week 0, week 4, week 16 and crossover to ustekinumab 45 mg at week 24, week 28 and week 40. At week 16, patients with <5% improvement in tender/swollen joint counts entered blinded early escape (placebo→45 mg, 45 mg→90 mg, 90 mg→90 mg). The primary endpoint was ≥20% improvement in American College of Rheumatology (ACR20) criteria at week 24. Secondary endpoints included week 24 Health Assessment Questionnaire-Disability Index (HAQ-DI) improvement, ACR50, ACR70 and ≥75% improvement in Psoriasis Area and Severity Index (PASI75). Efficacy was assessed in all patients, anti-TNF-naïve (n=132) patients and anti-TNF-experienced (n=180) patients. Results: More ustekinumab-treated (43.8% combined) than placebo-treated (20.2%) patients achieved ACR20 at week 24 (p<0.001). Significant treatment differences were observed for week 24 HAQ-DI improvement (p<0.001), ACR50 (p≤0.05) and PASI75 (p<0.001); all benefits were sustained through week 52. Among patients previously treated with ≥1 TNF inhibitor, sustained ustekinumab efficacy was also observed (week 24 combined vs placebo: ACR20 35.6% vs 14.5%, PASI75 47.1% vs 2.0%, median HAQ-DI change −0.13 vs 0.0; week 52 ustekinumab-treated: ACR20 38.9%, PASI75 43.4%, median HAQ-DI change −0.13). No unexpected adverse events were observed through week 60. Conclusions: The interleukin-12/23 inhibitor ustekinumab (45/90 mg q12 weeks) yielded significant and sustained improvements in PsA signs/symptoms in a diverse population of patients with active PsA, including anti-TNF-experienced PsA patients